This review will not encompass the effectiveness for GLP‐1 RA to reduce hospitalisation or mortality from macrovascular disease (such as heart failure) which has been covered extensively elsewhere16, 17; nor will it assess the usefulness of initiating GLP‐1 RA therapy in the months before surgery. This evidence concerns the gene GLP1R and heart failure.